SpayVac for Wildlife, Inc., in partnership with BioVaxys Technology Corp., has expanded production capacity at its Madison facility to support global demand for its fertility-control vaccines for animals, the company announced recently.

According to a release, the expansion will support wider SpayVac availability for field trials and market seeding studies as well as the launch of SpayVac in the near future.

“Part of our use of proceeds from ongoing fundraising will be to further scale up so we can produce tens of thousands of vaccines,” SpayVac CEO Tom D’Orazio said in a statement.

The vaccines include the established SpayVac pZP vaccine and a new GnRH vaccine for aquaculture and other species.